Tetrabenazine

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence supports a yellow grade (the single tetrabenazine-specific study found is a null result, see below), and no circulating consumer claim attributing mitochondrial damage to tetrabenazine specifically was located.
• Null finding on record: In the MN9D mammalian dopaminergic-cell study, tetrabenazine (1 µM) was dosed directly as a VMAT2-inhibitor comparator against the true mitochondrial toxins rotenone and antimycin A, and showed no significant effect on cell viability; the authors used this result to argue that dopamine depletion by tetrabenazine "followed a mechanism distinct from" mitochondrial Complex I/III inhibition. [4]

Channels tried

WebSearch (multiple phrasings: "tetrabenazine mitochondrial dysfunction study," "tetrabenazine ATP production energy metabolism," plus a follow-up on circulating mitochondrial-damage claims that could not be completed before an earlier session's search budget was exhausted). Crossref REST API ("tetrabenazine+mitochondria": one request rate-limited 429 and not retried; "tetrabenazine+mitochondrial+ATP": returned only USP monograph/reference-standard stubs and unrelated encyclopedia entries, a clean non-match). DailyMed/FDA label reviewed in full (Tier A; no mention of mitochondrial effects). Repair-pass addition: a direct PubMed search-listing fetch for "tetrabenazine AND (mitochondria OR mitochondrial OR ATP)" succeeded cleanly this pass, no bot-verification (58 results). [10] Page 1 of 6 was reviewed in full and remained dominated by Huntington's-disease-intrinsic bioenergetics and chorea-therapeutics literature. It surfaced one new tetrabenazine-specific hit, Caughey and Kirshner 1987, but that study measures vesicular ATP storage in a peripheral secretory system, not mitochondrial structure, membrane integrity, electron transport, or biogenesis, so it is graded under ATP production instead (see that entry and the Overlap map) and does not fill this category. Pages 2 through 6 of that result set were not exhaustively reviewed within this pass's time budget; a later revision should complete that review before treating this gap as fully settled.

Disease-intrinsic note

Huntington's disease itself has extensive, independently documented mitochondrial pathology (the rationale for coenzyme Q10 trials such as 2CARE in HD patients). That disease-intrinsic literature is not attributed to tetrabenazine here, per Hard Rule 2.

Limits on what this shows

• Key negative/null findings: In mammalian MN9D cells, tetrabenazine produced no significant rise in reactive oxygen species and no significant loss of viability; the antioxidant-response enzyme NQO1 decreased under tetrabenazine, the opposite direction from the increase seen under the true mitochondrial toxins rotenone and antimycin A in the same experiment. [4]
• At-risk subgroups: None established; no human subgroup data exists because no human study exists.

Regulatory status

The FDA label makes no mention of oxidative stress, redox markers, or antioxidant status for tetrabenazine. [1]

Population evidence

No human clinical data exists. (a) C. elegans genetic Huntington's-disease model (control strain AM134/Q0, non-pathogenic EAK102/Q15, pathogenic EAK103/Q128), tetrabenazine 100 µM in NGM agar from the L4 stage: tetrabenazine alone caused a significant decrease in survival in the Q0 control strain (n = 165 to 197 per arm across the four conditions); co-treatment with vitamin C 1 mM significantly increased survival versus tetrabenazine alone in the Q0 strain, and vitamin C alone or combined with tetrabenazine significantly improved survival distribution versus vehicle in the pathogenic Q128 strain (Mantel-Cox and Gehan-Breslow-Wilcoxon tests; significance bands of p<0.05 to p<0.0001 reported by condition, exact p-values not given in the source). [3] (b) Mammalian MN9D dopaminergic neuronal cell line, tetrabenazine 1 µM used as a VMAT2-inhibitor comparator alongside the mitochondrial toxins rotenone (1.5 µM, Complex I) and antimycin A (10 µM, Complex III): tetrabenazine did not significantly alter reactive-oxygen-species levels and had no significant effect on cell viability. [4]

Mechanism

Proposed, not established: VMAT2 inhibition raises cytosolic (non-vesicular) dopamine available for monoamine-oxidase-mediated deamination and auto-oxidation, generating reactive oxygen species. The source authors themselves caveat that "there is currently no direct association for vitamin C in the reduction of ROS produced by MAO" and that "the extent of ROS production resulting from TBZ treatment warrants further investigation in future studies." [3]

Counter-evidence held on record

Counter-evidence on record The only tetrabenazine-specific mammalian-cell data located found no significant oxidative-stress signal from tetrabenazine itself. [4] The worm-model finding supporting a signal is survival-based rather than a direct redox measurement, used a single high exposure concentration (100 µM) with no dose-response arm, and was obtained in a non-mammalian genetic-overexpression model; the authors explicitly flag the mechanism as unconfirmed. [3] Framing caution This is a preclinical, internally conflicting signal, not evidence that tetrabenazine depletes antioxidant capacity in people. The worm-model vitamin C co-treatment is a laboratory mechanistic tool, not a human dosing study, and must not be read as a basis for recommending vitamin C supplementation to any tetrabenazine patient; no clinical trial, dose, or safety data for that purpose exists.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence exists, and no circulating consumer claim names tetrabenazine for copper.

Channels tried

FDA label reviewed in full (Tier A; silent on copper). WebSearch ("tetrabenazine copper"), returning only chemistry-reagent and drug-reference pages unrelated to copper nutritional status. Crossref REST API ("tetrabenazine+copper"), returning only USP monograph/reference-standard entries and an unrelated SpringerReference encyclopedia stub, a clean non-match rather than a block. Repair-pass addition: a direct PubMed search-listing fetch for "tetrabenazine AND (copper OR iron)" succeeded cleanly this pass, no bot-verification (9 results, all reviewed). [11] One result, a 2014 Bioorg Med Chem Lett paper derivatizing dihydrotetrabenazine for copper-64 radiolabeling, was opened at the bibliographic level and confirmed to be PET-imaging radiochemistry, copper-64 used only as a radioisotope tag on a VMAT2-imaging tracer, irrelevant to copper nutritional status. [12] A second result, a 2026 Int J Biol Macromol paper on tetrabenazine binding to the metal-binding transport protein lactoferrin, could not be opened for its abstract or full text in this pass: Crossref, Europe PMC, and a direct PubMed re-fetch for it were all rate-limited (HTTP 429) repeatedly. Per protocol it is disclosed here as an unresolved lead, not cited as evidence for or against a copper finding. [18] Direct PubMed/PMC full-text fetches of candidate primary studies were also blocked by reCAPTCHA bot-verification on earlier attempts; the search-listing channel above worked even when full-text fetches did not.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence exists, and no circulating consumer claim names tetrabenazine for iron or iron-deficiency anemia.

Channels tried

FDA label reviewed in full (Tier A; the adverse-reaction sections reviewed contain no mention of anemia, hemoglobin, hematocrit, or blood-cell counts). WebSearch ("tetrabenazine iron deficiency anemia"), returning only generic iron-deficiency reference pages with no tetrabenazine-specific content. Crossref REST API ("tetrabenazine+iron"), returning only USP monograph/reference-standard entries, a clean non-match. Repair-pass addition: the same direct PubMed search-listing fetch for "tetrabenazine AND (copper OR iron)" succeeded cleanly this pass (9 results, all reviewed). [11] Three results were disease-intrinsic differential-diagnosis literature, not drug-caused findings, and are excluded on that basis: Wilson's disease, a copper-storage disorder that presents with chorea for which tetrabenazine is a symptomatic treatment option, not a cause of iron or copper change [13]; neuroferritinopathy and aceruloplasminemia, genetic brain-iron-overload disorders that can present with chorea and may be symptomatically treated with VMAT2 inhibitors, with the iron pathology intrinsic to the disease rather than the drug [14,15]. As with Copper, a 2026 tetrabenazine-lactoferrin biophysical study surfaced in the same search but could not be opened in this pass (Crossref, Europe PMC, and a PubMed abstract re-fetch were all rate-limited); disclosed as an unresolved lead for a later revision, not cited as evidence. [18] Direct PubMed/PMC full-text fetches of candidate primary studies were also blocked by reCAPTCHA bot-verification on earlier attempts.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence exists, and no circulating consumer claim names tetrabenazine for gut-microbiome effects.

Mechanism screen

Tetrabenazine has no documented antimicrobial, acid-suppressing, or GI-transit-altering property in the reviewed label; Step 2 mechanism class G (microbiome disruption affecting endogenous nutrient synthesis) screens as absent on current evidence.

Channels tried

WebSearch ("tetrabenazine gut microbiome"), returning only generic microbiome-biology pages unrelated to this drug. Crossref REST API ("tetrabenazine+microbiome+gut"), returning only unrelated microbiome-journal titles and table-of-contents entries, a clean non-match. Repair-pass addition: a direct PubMed search-listing fetch for "tetrabenazine AND (microbiome OR microbiota)" was re-run in this pass and returned an explicit, clean zero-result page (page metadata confirmed "meta-log_resultcount: 0" and "meta-ncbi_pdid: emptyresult") rather than a bot-verification block. [16] This is now the cleanest, most confidently genuine gap in the dossier: every channel tried worked as intended and returned nothing, rather than being blocked.

Limits on what this shows

• Key negative/null findings: The ATP reduction did not track linearly with the magnitude of catecholamine depletion, which the original authors used to argue the two pools are regulated somewhat independently rather than the ATP loss being a simple passive consequence of monoamine loss. [9]
• At-risk subgroups: None established; no human data exists for this finding in any population.

Regulatory status

The FDA label makes no mention of ATP, cellular energy metabolism, or fatigue as a mechanistic finding for tetrabenazine. [1]

Population evidence

In vitro only. Cultured bovine adrenal medullary chromaffin cells, three-day treatment with tetrabenazine or reserpine: both drugs caused 85 to 90 percent depletion of stored catecholamines and a 41 to 46 percent reduction in total cellular ATP content. The authors' evidence pointed to the ATP loss occurring primarily within the chromaffin secretory vesicles, the same vesicles whose monoamine transport tetrabenazine blocks, rather than scaling proportionally with the catecholamine loss itself. [9] This is tetrabenazine-specific (cohort test passed, tetrabenazine was dosed directly alongside reserpine) but non-human, decades old, and confined to a peripheral neuroendocrine cell type that is not the drug's clinical target tissue (striatal dopaminergic terminals).

Mechanism

Chromaffin secretory vesicles normally co-store ATP alongside catecholamines as part of the vesicular matrix. Tetrabenazine's intended action, blocking VMAT2-mediated vesicular monoamine uptake, is a distinct molecular event from mitochondrial oxidative phosphorylation; this finding describes a secondary reduction in vesicular ATP content in a peripheral cell model, not a measured change in mitochondrial ATP synthesis capacity, and it is reported separately from, and must not be merged with, the Mitochondrial burden entry below, which rests on an entirely different source and assay.

Counter-evidence held on record

Counter-evidence on record The same-class MN9D dopaminergic-cell study used elsewhere in this dossier measured ATP/energy-depletion endpoints only for the mitochondrial toxins rotenone and antimycin A, not for the tetrabenazine comparator arm, so it neither confirms nor contradicts this chromaffin-cell finding. [4] No human or clinical measurement of ATP, energy expenditure, or fatigue has been performed in tetrabenazine-treated patients. Framing caution This is a 1987 peripheral-tissue, non-human, vesicular-storage finding, not evidence that tetrabenazine lowers whole-body energy production, causes fatigue, or depletes ATP in human neurons or muscle. It must not be read as grounds for any ATP-boosting or energy-support supplement recommendation; no such recommendation is made anywhere in this dossier.

Limits on what this shows

• Why no grade: Dual condition met: no Tier B/C evidence exists, and no circulating consumer claim names tetrabenazine for hemoglobin, hematocrit, or oxygen delivery.

Tier A data reviewed

The adverse-reaction sections of the FDA label reviewed in this pass contain no mention of hemoglobin, hematocrit, anemia, or blood-cell counts. This is an absence of a reported signal in the labeled safety data, not a finding of safety, and is disclosed as such rather than reworded into reassurance. [1]

Channels tried

WebSearch ("tetrabenazine hemoglobin hematocrit red blood cell"), returning only generic hematology-reference pages with no tetrabenazine-specific content. Crossref REST API ("tetrabenazine+hemoglobin+oxygen"), returning only unrelated hemoglobin-biochemistry and hemoglobin-based-oxygen-carrier therapeutics book chapters, a clean non-match. Repair-pass addition: a direct PubMed search-listing fetch for "tetrabenazine AND (hemoglobin OR anemia OR hematocrit OR oxygen)" succeeded cleanly this pass, no bot-verification (13 results, all reviewed by title and abstract snippet). [17] None support a drug-caused finding: results were dominated by McLeod neuroacanthocytosis syndrome (a disease-intrinsic chorea differential diagnosis with its own acanthocytosis/hemolysis biology, unrelated to drug causation), a report of tetrabenazine reducing cyanotic episodes of an unrelated paroxysmal disorder (a therapeutic effect of treating that disorder, not a nutrient-pathway finding), and several mechanistically unrelated hits (dopamine-mediated insulin secretion, PET motion correction, beta-cell imaging, a pimozide case report, an unrelated herbal-extract neuroprotection study), alongside the two sources already cited elsewhere in this dossier. [3,4] This confirms the ungraded disclosure on a channel that worked cleanly this time, not one that was blocked.